MedTrace Logo

Safety and Efficacy of ARQ-252 Cream in Subjects With Chronic Hand Eczema

NCT04378569 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 230

Last updated 2024-04-05

Study results available
· View outcomes & findings →

Summary

This study will assess the safety and efficacy of ARQ-252 cream in subjects with chronic hand eczema

Conditions

  • Chronic Hand Eczema

Interventions

DRUG

ARQ-252 cream 0.3%

ARQ-252 cream 0.3%

DRUG

ARQ-252 cream 0.1%

ARQ-252 cream 0.1%

DRUG

ARQ-252 Vehicle Cream

ARQ-252 Vehicle Cream

Sponsors & Collaborators

  • Arcutis Biotherapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • David Berk, MD · Arcutis Biotherapeutics, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-20
Primary Completion
2021-02-24
Completion
2021-02-24
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04378569 on ClinicalTrials.gov